This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Bristol-Myers Squibb Company

Drug Names(s): anti-PDL-1, anti-PD-L1, MDX1105

Description: MDX-1105 is a fully human monoclonal antibody that binds to PD-L1 (Programmed Death-1 Ligand 1), blocking its binding to and activation of its receptor, PD-1 (Programmed Death 1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation in chronic infectious disease. PD-L1 is expressed broadly on hematopoietic and parenchymal tissues; PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.

Deal Structure: MDX-1105 was originally developed by Medarex.

In July 2009, Bristol-Myers Squibb and Medarex announced that the companies signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16.00 per share in cash. In September 2009, Bristol-Myers Squibb completed its acquisition of Medarex.

BMS-936559 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug